AMENDMENT 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 6th, 2024 • Context Therapeutics Inc. • Pharmaceutical preparations
THIS AMENDMENT 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment”), is entered into as of the 29th day of February, 2024 (“Amendment Effective Date”) by and between Integral Molecular, Inc., a Delaware corporation (“Integral”), having its principal place of business at One uCity Square, 25 North 38th St. Suite 800, Philadelphia, PA 19104, and Context Therapeutics, LLC, a company organized under the laws of Delaware (“Context”), having its principal place of business at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103.
